Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00699491 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

48

Enrollment

NIH

Sponsor class

Conditions

Male Breast Carcinoma
Recurrent Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7

Interventions

BIOLOGICAL: Cixutumumab
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Temsirolimus

Sponsor

National Cancer Institute (NCI)